Benzinga - by Priya Nigam, Benzinga Staff Writer.
AbbVie Inc (NYSE: ABBV) is acquiring ImmunoGen, Inc. (NASDAQ: IMGN) for around $10 billion.
The deal, which is expected to close in mid-2024, represents a “great price” for ImmunoGen, at $31.26 per share, according to Piper Sandler.
The ImmunoGen Analyst: Joseph Catanzaro downgraded the rating for ImmunoGen from Overweight to Neutral, while raising the price target from $24 to $31.
Check out other analyst stock ratings.
The ImmunoGen Thesis: The AbbVie deal has come at the right time, as ImmunoGen enters 2024 “with questions around when the Elahere launch might hit a ceiling given its robust uptake,” Catanzaro said in the downgrade note.
A competing bid is unlikely to appear, “as we think something north of the ABBV offer would be difficult for any interested party to justify,” the analyst wrote.
“IMGN's ADC platform/pipeline complement ABBV's oncology franchise, specifically filling a gap in ovarian cancer and augmenting its presence in solid tumors, along with complementary ADC technologies,” he added.
“We downgrade to Neutral and raise our price target to $31 to reflect the deal terms,” Catanzaro stated.
IMGN Price Action: Shares of ImmunoGen had declined by 0.53% to $29.16 at the time of publication on Monday.
Now Read: Dow's New All-Time-High: DIA Outperforms SPY In November
Latest Ratings for IMGN
| Feb 2022 | SVB Leerink | Maintains | Market Perform | |
| Feb 2022 | BMO Capital | Initiates Coverage On | Outperform | |
| Dec 2021 | Jefferies | Upgrades | Hold | Buy |
View the Latest Analyst Ratings
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga